Dinaciclib caused significant tumor regression (%TGI  = 191%) in the MCL1:BCL-xL high mRNA ratio and MCL1-dependent NCI-H23 xenograft model (Figures 5C and S6). The gene discussed is BCL2L1; the disease is neoplasm.